CA Patent

CA3207917A1 — Recombinant human acid alpha-glucosidase and uses thereof

Assigned to Amicus Therapeutics Inc · Expires 2022-08-18 · 4y expired

What this patent protects

Provided herein are methods of treating Pompe disease comprising administering a population of recombinant human acid a-glucosidase molecules or a pharmaceutical composition or formulation thereof, and a pharmacological chaperone.

USPTO Abstract

Provided herein are methods of treating Pompe disease comprising administering a population of recombinant human acid a-glucosidase molecules or a pharmaceutical composition or formulation thereof, and a pharmacological chaperone.

Drugs covered by this patent

Patent Metadata

Patent number
CA3207917A1
Jurisdiction
CA
Classification
—
Expires
2022-08-18
Drug substance claim
No
Drug product claim
No
Assignee
Amicus Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.